Nebivolol

A multifaceted antioxidant and cardioprotectant in hypertensive heart disease

M. Usman Khan, Wenyuan Zhao, Tieqiang Zhao, Fahed Al Darazi, Robert A. Ahokas, Yao Sun, Syamal Bhattacharya, Ivan Gerling, Karl Weber

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Cardiomyocyte necrosis with attendant microscopic scarring is a pathological feature of human hypertensive heart disease (HHD). Understanding the pathophysiological origins of necrosis is integral to its prevention. In a rat model of HHD associated with aldosterone/salt treatment (ALDOST), myocyte necrosis is attributable to oxidative stress induced by cytosolic-free [Ca]i and mitochondrial [Ca]m overloading in which the rate of reactive oxygen species generation overwhelms their rate of detoxification by endogenous Zn-based antioxidant defenses. We hypothesized that nebivolol (Neb), unlike another β1 adrenergic receptor antagonist atenolol (Aten), would have a multifaceted antioxidant potential based on its dual property as a β3 receptor agonist, which activates endothelial nitric oxide synthase to stimulate nitric oxide (NO) generation. NO promotes the release of cytosolic Zn sequestered inactive by its binding protein, metallothionein. Given the reciprocal regulation between these cations, increased [Zn]i reduces Ca entry and attendant rise in [Ca]i and [Ca]m. Herein, we examined the antioxidant and cardioprotectant properties of Neb and Aten in rats receiving 4 weeks ALDOST. Compared with untreated age-/sex-matched controls, ALDOST alone or ALDOST with Aten, Neb cotreatment induced endothelial nitric oxide synthase activation, NO generation and a marked increase in [Zn]i with associated decline in [Ca]i and [Ca]m. Attendant antioxidant profile at subcellular and cellular levels included attenuation of mitochondrial H2O2 production and lipid peroxidation expressed as reduced 8-isoprostane concentrations in both mitochondria and cardiac tissue. Myocyte salvage was expressed as reduced microscopic scarring and tissue collagen volume fraction. Neb is a multifaceted antioxidant with unique properties as cardioprotectant in HHD.

Original languageEnglish (US)
Pages (from-to)445-451
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume62
Issue number5
DOIs
StatePublished - Nov 1 2013

Fingerprint

Nebivolol
Heart Diseases
Aldosterone
Antioxidants
Atenolol
Salts
Nitric Oxide
8-epi-prostaglandin F2alpha
Necrosis
Nitric Oxide Synthase Type III
Muscle Cells
Cicatrix
Adrenergic Antagonists
Metallothionein
Cardiac Myocytes
Lipid Peroxidation
Cations
Reactive Oxygen Species
Carrier Proteins
Mitochondria

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Nebivolol : A multifaceted antioxidant and cardioprotectant in hypertensive heart disease. / Khan, M. Usman; Zhao, Wenyuan; Zhao, Tieqiang; Al Darazi, Fahed; Ahokas, Robert A.; Sun, Yao; Bhattacharya, Syamal; Gerling, Ivan; Weber, Karl.

In: Journal of Cardiovascular Pharmacology, Vol. 62, No. 5, 01.11.2013, p. 445-451.

Research output: Contribution to journalArticle

Khan, M. Usman ; Zhao, Wenyuan ; Zhao, Tieqiang ; Al Darazi, Fahed ; Ahokas, Robert A. ; Sun, Yao ; Bhattacharya, Syamal ; Gerling, Ivan ; Weber, Karl. / Nebivolol : A multifaceted antioxidant and cardioprotectant in hypertensive heart disease. In: Journal of Cardiovascular Pharmacology. 2013 ; Vol. 62, No. 5. pp. 445-451.
@article{d4f6327f1b3d4a2690d447dbd6c904ca,
title = "Nebivolol: A multifaceted antioxidant and cardioprotectant in hypertensive heart disease",
abstract = "Cardiomyocyte necrosis with attendant microscopic scarring is a pathological feature of human hypertensive heart disease (HHD). Understanding the pathophysiological origins of necrosis is integral to its prevention. In a rat model of HHD associated with aldosterone/salt treatment (ALDOST), myocyte necrosis is attributable to oxidative stress induced by cytosolic-free [Ca]i and mitochondrial [Ca]m overloading in which the rate of reactive oxygen species generation overwhelms their rate of detoxification by endogenous Zn-based antioxidant defenses. We hypothesized that nebivolol (Neb), unlike another β1 adrenergic receptor antagonist atenolol (Aten), would have a multifaceted antioxidant potential based on its dual property as a β3 receptor agonist, which activates endothelial nitric oxide synthase to stimulate nitric oxide (NO) generation. NO promotes the release of cytosolic Zn sequestered inactive by its binding protein, metallothionein. Given the reciprocal regulation between these cations, increased [Zn]i reduces Ca entry and attendant rise in [Ca]i and [Ca]m. Herein, we examined the antioxidant and cardioprotectant properties of Neb and Aten in rats receiving 4 weeks ALDOST. Compared with untreated age-/sex-matched controls, ALDOST alone or ALDOST with Aten, Neb cotreatment induced endothelial nitric oxide synthase activation, NO generation and a marked increase in [Zn]i with associated decline in [Ca]i and [Ca]m. Attendant antioxidant profile at subcellular and cellular levels included attenuation of mitochondrial H2O2 production and lipid peroxidation expressed as reduced 8-isoprostane concentrations in both mitochondria and cardiac tissue. Myocyte salvage was expressed as reduced microscopic scarring and tissue collagen volume fraction. Neb is a multifaceted antioxidant with unique properties as cardioprotectant in HHD.",
author = "Khan, {M. Usman} and Wenyuan Zhao and Tieqiang Zhao and {Al Darazi}, Fahed and Ahokas, {Robert A.} and Yao Sun and Syamal Bhattacharya and Ivan Gerling and Karl Weber",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/FJC.0b013e3182a0b5ff",
language = "English (US)",
volume = "62",
pages = "445--451",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nebivolol

T2 - A multifaceted antioxidant and cardioprotectant in hypertensive heart disease

AU - Khan, M. Usman

AU - Zhao, Wenyuan

AU - Zhao, Tieqiang

AU - Al Darazi, Fahed

AU - Ahokas, Robert A.

AU - Sun, Yao

AU - Bhattacharya, Syamal

AU - Gerling, Ivan

AU - Weber, Karl

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Cardiomyocyte necrosis with attendant microscopic scarring is a pathological feature of human hypertensive heart disease (HHD). Understanding the pathophysiological origins of necrosis is integral to its prevention. In a rat model of HHD associated with aldosterone/salt treatment (ALDOST), myocyte necrosis is attributable to oxidative stress induced by cytosolic-free [Ca]i and mitochondrial [Ca]m overloading in which the rate of reactive oxygen species generation overwhelms their rate of detoxification by endogenous Zn-based antioxidant defenses. We hypothesized that nebivolol (Neb), unlike another β1 adrenergic receptor antagonist atenolol (Aten), would have a multifaceted antioxidant potential based on its dual property as a β3 receptor agonist, which activates endothelial nitric oxide synthase to stimulate nitric oxide (NO) generation. NO promotes the release of cytosolic Zn sequestered inactive by its binding protein, metallothionein. Given the reciprocal regulation between these cations, increased [Zn]i reduces Ca entry and attendant rise in [Ca]i and [Ca]m. Herein, we examined the antioxidant and cardioprotectant properties of Neb and Aten in rats receiving 4 weeks ALDOST. Compared with untreated age-/sex-matched controls, ALDOST alone or ALDOST with Aten, Neb cotreatment induced endothelial nitric oxide synthase activation, NO generation and a marked increase in [Zn]i with associated decline in [Ca]i and [Ca]m. Attendant antioxidant profile at subcellular and cellular levels included attenuation of mitochondrial H2O2 production and lipid peroxidation expressed as reduced 8-isoprostane concentrations in both mitochondria and cardiac tissue. Myocyte salvage was expressed as reduced microscopic scarring and tissue collagen volume fraction. Neb is a multifaceted antioxidant with unique properties as cardioprotectant in HHD.

AB - Cardiomyocyte necrosis with attendant microscopic scarring is a pathological feature of human hypertensive heart disease (HHD). Understanding the pathophysiological origins of necrosis is integral to its prevention. In a rat model of HHD associated with aldosterone/salt treatment (ALDOST), myocyte necrosis is attributable to oxidative stress induced by cytosolic-free [Ca]i and mitochondrial [Ca]m overloading in which the rate of reactive oxygen species generation overwhelms their rate of detoxification by endogenous Zn-based antioxidant defenses. We hypothesized that nebivolol (Neb), unlike another β1 adrenergic receptor antagonist atenolol (Aten), would have a multifaceted antioxidant potential based on its dual property as a β3 receptor agonist, which activates endothelial nitric oxide synthase to stimulate nitric oxide (NO) generation. NO promotes the release of cytosolic Zn sequestered inactive by its binding protein, metallothionein. Given the reciprocal regulation between these cations, increased [Zn]i reduces Ca entry and attendant rise in [Ca]i and [Ca]m. Herein, we examined the antioxidant and cardioprotectant properties of Neb and Aten in rats receiving 4 weeks ALDOST. Compared with untreated age-/sex-matched controls, ALDOST alone or ALDOST with Aten, Neb cotreatment induced endothelial nitric oxide synthase activation, NO generation and a marked increase in [Zn]i with associated decline in [Ca]i and [Ca]m. Attendant antioxidant profile at subcellular and cellular levels included attenuation of mitochondrial H2O2 production and lipid peroxidation expressed as reduced 8-isoprostane concentrations in both mitochondria and cardiac tissue. Myocyte salvage was expressed as reduced microscopic scarring and tissue collagen volume fraction. Neb is a multifaceted antioxidant with unique properties as cardioprotectant in HHD.

UR - http://www.scopus.com/inward/record.url?scp=84888130953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888130953&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3182a0b5ff

DO - 10.1097/FJC.0b013e3182a0b5ff

M3 - Article

VL - 62

SP - 445

EP - 451

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 5

ER -